4 rue Pierre Fontaine
91058 EVRY Cedex – France
Email : firstname.lastname@example.org
Zakia BELAID-SANDAL : CEO
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases
Young and multidisciplinary French start-up, THERANOVIR develops immunotherapeutic innovative antibodies for three diversified and interconnected pathologies:
This project is the result of academic research
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
The main axe of THERANOVIR is oncology. THERANOVIR is developing innovative therapeutic monoclonal antibodies targeting both tumor cells (stem and non-stem) and cells of the microenvironment in combination with a companion immunohistological test. Being in the preclinical phases, candidates under development will be proposed in combination in response to therapeutic failures of checkpoint inhibitors and / or anti-angiogenesis in combination with chemotherapy.
At the same time, THERANOVIR is progressing in the development of immunotherapeutic antibodies targeting obesity.
THERANOVIR is currently looking for funding to progress in the preclinical development in order to enter the regulatory and the clinical phases.
We are interested to tie partnerships with big pharma to ensure the development of our products in clinical phases and beyond.
In same field
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.Discover
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).Discover
Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.Discover
GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.Discover
By means of its autonomous messenger RNA synthesis platform, Eukarÿs develops 1) systems for the bioproduction of viruses and recombinant proteins and 2) preventative vaccines for viral infectious diseases and treatments in immuno-oncology.Discover
Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.Discover
Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.Discover